Home CONTACT Neoplasma 2009 Neoplasma Vol.56, No.2, p.150-155, 2009

Journal info


6 times a year.
Founded: 1954
ISSN 0028-2685
ISSN 1338-4317 (online)

Published in English

Editorial Info
Abstracted and Indexed
Submission Guidelines

Select Journal







Webshop Cart

Your Cart is currently empty.

Info: Your browser does not accept cookies. To put products into your cart and purchase them you need to enable cookies.

Neoplasma Vol.56, No.2, p.150-155, 2009

Title: Anal cancer chemoirradiation with curative intent – a single institution experience
Author: I. Oblak, P. Petric, F. Anderluh, V. Velenik, R. Hudej, A. P. Fras

Abstract: Results of radiochemotherapy in 50 patients with squamous cell carcinoma of the anal canal, treated with radical radiochemotherapy between January 2003 and September 2007, at the Institute of Oncology Ljubljana are presented. The treatment schedule consisted of 3-D conformal external beam radiotherapy (45 Gy in 25 fractions), with two cycles of concurrent chemotherapy (5-fluorouracil (5-FU) / Mitomycin C), followed by brachytherapy or external beam boost (15-30 Gy) to the primary tumor. Locoregional control (LRC), disease-free survival (DFS), disease-specific survival (DSS), overall survival (OS) and colostomy-free survival (CFS) rates and the rate of acute and chronic side-effects were estimated. The impact of individual tumor- and therapy-related factors on treatment outcome was assessed.

Treatment was completed according to the protocol in 72% of patients. The median follow-up time of 40 survivors was 22 months (range 1.7-53.2 months). At 2 years, LRC, DFS, DSS, OS and CFS rates were 68%, 67%, 87%, 76% and 85%, respectively. In the multivariate analysis, nodal stage was identified as an independent prognostic factor for LRC, DSS and CFS and application of Mitomycin C for OS. The most frequent acute side-effect of treatment was radiodermatitis (grade 3 in 66% of patients, grade 4 in 2%). Late anal stenosis, chronic ulceration and grade 2-3 incontinence developed in 3 (6 %), 2 (4 %) and 5 (10 %) of colostomy-free survivors, respectively.

Radiotherapy with concurrent 5-FU / Mitomycin C chemotherapy is feasible, with acceptable toxicity. The presented treatment outcome is comparable to other published results.



Keywords: anal cancer, radiochemotherapy, survival, toxicity
Year: 2009, Volume: 56, Issue: 2 Page From: 150, Page To: 155
doi:10.4149/neo_2009_02_150
Price: 14.40 €






© AEPress s.r.o
Copyright notice: For any permission to reproduce, archive or otherwise use the documents in the ELiS, please contact AEP.